Search results for " Diabetes Mellitus"

showing 10 items of 309 documents

Cellular and molecular basis of the imbalance between vascular damage and repair in ageing and age-related diseases: As biomarkers and targets for ne…

2016

Preclinical and clinical studies suggest that specific subsets of cells isolated from the peripheral blood, play an essential role in the imbalance of damage and repair during age-associated diseases, such as metabolic syndrome, diabetes, atherosclerosis, neurodegenerative diseases, osteoporosis and cancer. Endogenous regeneration of the vessel wall involves cells of the vascular wall, inflammatory cells, circulating precursors, and mature endothelial cells, which are capable to restore the endothelium in a concerted interaction. Early detection of such imbalances with specific biomarkers may reduce age-associated diseases and subsequent cardiovascular events. Likewise, new strategies have …

0301 basic medicineAgingEndotheliumCellStimulationBiologyVascular disease03 medical and health sciencesDiabetes mellitusStem and progenitor cellsNeoplasmsmedicineBiomarkers TumorDiabetes MellitusStem and progenitor cells Biomarkers Ageing Vascular diseaseAnimalsHumansMetabolic SyndromeTumorVascular diseaseEndogenous regenerationCancerNeurodegenerative Diseasesmedicine.diseaseAtherosclerosisAgeing; Biomarkers; Stem and progenitor cells; Vascular disease; Animals; Biomarkers Tumor; Humans; Aging; Atherosclerosis; Diabetes Mellitus; Metabolic Syndrome; Neoplasms; Neurodegenerative Diseases; OsteoporosisAgeing030104 developmental biologymedicine.anatomical_structureAgeingImmunologyCancer researchOsteoporosisBiomarkersDevelopmental Biology
researchProduct

Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor.

2021

Cardiovascular outcome trials revealed cardiovascular benefits for type 2 diabetes mellitus patients when treated with long-acting glucagon-like peptide-1 (GLP-1) receptor agonists. In the last decade, major advances were made characterising the physiological effects of GLP-1 and its action on numerous targets including brain, liver, kidney, heart and blood vessels. However, the effects of GLP-1 and receptor agonists, and the GLP-1 receptor on the cardiovascular system have not been fully elucidated. We compare results from cardiovascular outcome trials of GLP-1 receptor agonists and review pleiotropic clinical and preclinical data concerning cardiovascular protection beyond glycaemic contr…

0301 basic medicineAgonistendocrine systemmedicine.drug_classDiseasePharmacologyCardiovascular SystemGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineGlucagon-Like Peptide 1Diabetes mellitusMedicineHumansHypoglycemic AgentsReceptorGlucagon-like peptide 1 receptorPharmacologyKidneybusiness.industrydigestive oral and skin physiologyType 2 Diabetes Mellitusmedicine.diseaseGlucagon-like peptide-1030104 developmental biologymedicine.anatomical_structureDiabetes Mellitus Type 2Cardiovascular Diseasesbusinesshormones hormone substitutes and hormone antagonists030217 neurology & neurosurgeryBritish journal of pharmacology
researchProduct

Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus

2021

Diabetes represents the leading risk factor for the development of cardiovascular disease (CVD). Chronic hyperglycemia and/or acute post-prandial changes in blood glucose determine an increase in reactive oxygen species (ROS), which play a fundamental role in endothelial dysfunction and in the nuclear transport of pro-atherogenic transcription factors that activate the "inflammasome". In addition, the glycemic alteration favors the formation and stabilization of atherosclerotic plaque through the mechanism of non-enzymatic glycation of different molecules, with the establishment of the so-called "advanced glycosylation end products" (AGE). Laboratory information provided by the level of bio…

0301 basic medicineBlood GlucoseNovel biomarkersDisease030204 cardiovascular system & hematologyBioinformatics03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGlycationRisk FactorsDiabetes mellitusType 2 diabetes mellitusMedicineHumansEndothelial dysfunctionRisk factorMolecular BiologyGlycemicInflammationGlycationbusiness.industryType 2 Diabetes Mellitusmedicine.diseaseCardiovascular risk030104 developmental biologychemistryDiabetes Mellitus Type 2Cardiovascular DiseasesOxidative stressMolecular MedicineAdvanced glycation end-productbusinessReactive Oxygen SpeciesBiomarkers
researchProduct

Weight loss programmes using low carbohydrate diets to control the cardiovascular risk in adolescents (Review).

2020

Cardiovascular risk (CVR) is a broad term that includes traditional factors like hypertension, hyper lipidemia, abdominal obesity, hyperinsulinemia or overt type 2 diabetes mellitus (T2DM), and emerging ones such as hypothyroidism or inflammatory diseases. In epidemiologic studies, all of these factors are associated with atherogenesis and have complex interactions between them. They have in common an increased prevalence in the general population beginning in childhood, and are correlated with endothelial damage as demonstrated by echocardiographic modifications of the left ventricle or carotid intima-media thickness. Adolescence is a transition period where behavioural eating patterns dev…

0301 basic medicineCancer ResearchPediatricsmedicine.medical_specialtyPopulationType 2 diabetesReviewOverweight03 medical and health sciences0302 clinical medicineImmunology and Microbiology (miscellaneous)Weight lossmedicineHyperinsulinemiaeducationAbdominal obesityeducation.field_of_studybusiness.industryType 2 Diabetes MellitusGeneral Medicinemedicine.disease030104 developmental biology030220 oncology & carcinogenesismedicine.symptombusinessDyslipidemiaExperimental and therapeutic medicine
researchProduct

INFLAMMATORY BOWEL DISEASE, COLORECTAL CANCER AND TYPE 2 DIABETES MELLITUS: THE LINKS

2016

The co-occurrence of the three disease entities, inflammatory bowel disease (IBD), colorectal cancer (CRC), type 2diabetes mellitus (T2DM) along with inflammation and dismicrobism has been frequently reported. Some authors have even suggested that dysbiosis could be the link through a molecular crosstalk of multiple inflammatory loops including TGFβ, NFKB, TNFα and ROS among others. This review focuses on the inflammatory process along with the role of microbiota in the pathophysiology of the three diseases. The etiology of IBD is multifactorial, and like CRC and T2DM, it is associated with a widespread and sustained GI inflammation and dismicrobism, whereby an array of pro-inflammatory med…

0301 basic medicineColorectal cancerIBDT2DMInflammationDiseaseReviewSystemic inflammationProbioticInflammatory bowel diseasePathology and Forensic MedicinePathogenesis03 medical and health sciences0302 clinical medicinePhysiology (medical)medicineInflammationbusiness.industrymedicine.diseasedigestive system diseasesCRC030104 developmental biology030220 oncology & carcinogenesisImmunologyInflammatory Bowel diseases IBD colorectal cancer diabetes mellitusMolecular MedicineDysbiosisTumor necrosis factor alphamedicine.symptombusinessDysbiosis
researchProduct

Use of Troponin as a predictor for cardiovascular diseases in patients with type 2 Diabetes Mellitus

2020

People with type 2 diabetes mellitus (T2DM) have two- to four-fold increased cardiovascular mortality in comparison to the general population. With the identification of new therapeutic targets and hypoglycemic drugs for T2DM, the need for a better stratification of CVD risk has emerged to select patients who may need intensive or specific treatment. At present, risk stratification is based on clinical, demographic, and biochemical factors. High sensitivity cardiac troponin (hs-cTn) increases after several ischemic and non-ischemic insults and it is considered a marker of myocardial injury. This review summarizes the main findings about hs-cTn utilization for risk stratification in people w…

0301 basic medicineDiabetes mellitumedicine.medical_specialtyendocrine system diseasesClinical BiochemistryPopulationSettore MED/49Biochemistrylaw.invention03 medical and health sciencesDiabetes mellitus0302 clinical medicineRandomized controlled triallawDiabetes mellitusmedicineHumansIn patientIntensive care medicineeducationLife StyleCardiovascular mortalityClinical Trials as Topiceducation.field_of_studyPrimary preventionbiologybusiness.industryBiochemistry (medical)Type 2 Diabetes MellitusBiomarkerGeneral MedicineCardiovascular diseasePrognosismedicine.diseaseTroponinTroponinSettore BIO/12 - Biochimica Clinica E Biologia Molecolare Clinica030104 developmental biologyRisk factorsDiabetes Mellitus Type 2Cardiovascular Diseases030220 oncology & carcinogenesisbiology.proteinObservational studyRisk factorbusinessBiomarkersClinica Chimica Acta
researchProduct

Effects of quality and quantity of protein intake for type 2 Diabetes Mellitus prevention and metabolic control

2020

Purpose of Review: The aim of this review is to evaluate the ideal protein quality and quantity and the dietary composition for the prevention and metabolic control of type 2 diabetes mellitus (T2DM). Introduction: Although some reviews demonstrate the advantages of a diet with a higher protein intake, other reviews have observed that a diet high in carbohydrates, with low-glycaemic index carbohydrates and good fibre intake, is equally effective in improving insulin sensitivity. Methods: Over 2831 articles were screened, and 24 from the last 5 years were analysed and summarised for this review, using the protein, diabetes and insulin glucose metabolic keywords in Pubmed in June 2019. Result…

0301 basic medicineDietary FiberMeatDatabases Factualmedicine.medical_treatmentPhysiology030209 endocrinology & metabolismType 2 diabetesDiet; Intake; Protein; Quality; Type 2 diabetesSettore MED/4903 medical and health sciencesEating0302 clinical medicineSettore MED/13Diabetes mellitusmedicineAnimalsHumansMetabolic Syndrome030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryInsulinProteinType 2 Diabetes MellitusProteinsType 2 diabetesmedicine.diseaseQualityDietDiabetes Mellitus Type 2Plant proteinGlycemic IndexMetabolic control analysisIntakeDairy ProductsMetabolic syndromeInsulin ResistancebusinessProtein qualityFood Science
researchProduct

Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis

2020

International audience; The mechanisms that drive nonalcoholic fatty liver disease (NAFLD) remain incompletely understood. This large multicenter study characterized the transcriptional changes that occur in liver tissue across the NAFLD spectrum as disease progresses to cirrhosis to identify potential circulating markers. We performed high-throughput RNA sequencing on a discovery cohort comprising histologically characterized NAFLD samples from 206 patients. Unsupervised clustering stratified NAFLD on the basis of disease activity and fibrosis stage with differences in age, aspartate aminotransferase (AST), type 2 diabetes mellitus, and carriage of PNPLA3 rs738409 , a genetic variant assoc…

0301 basic medicineLiver CirrhosisCirrhosis[SDV]Life Sciences [q-bio]DiseaseBiologyTranscriptome03 medical and health sciences0302 clinical medicineFibrosisnashNon-alcoholic Fatty Liver DiseaseDiabetes mellitusNonalcoholic fatty liver diseasemedicineDiabetes MellitusHumansGeneral Medicinemedicine.disease3. Good health030104 developmental biologyDiabetes Mellitus Type 2LiverHumans; Liver; Liver Cirrhosis; Transcriptome; Diabetes Mellitus Type 2; Non-alcoholic Fatty Liver DiseaseImmunology030211 gastroenterology & hepatologyGDF15SteatohepatitisTranscriptomeType 2
researchProduct

Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study

2018

Purpose: Proper evaluation of polyphenols intake at the population level is a necessary step in order to establish possible associations with health outcomes. Available data are limited, and so far no study has been performed in people with diabetes. The aim of this work was to document the intake of polyphenols and their major food sources in a cohort of people with type 2 diabetes and in socio-demographic subgroups. Methods: We studied 2573 men and women aged 50–75 years. Among others, anthropometry was measured by standard protocol and dietary habits were investigated by food frequency questionnaire (EPIC). The intake of polyphenols was evaluated using US Department of Agriculture and Ph…

0301 basic medicineMaleAge BMI Diabetes Diet Flavonoids Food groups Geographical area Intake Phenolic acids Polyphenols TOSCA.IT study Aged Antioxidants Beverages Cinnamates Cohort Studies Cross-Sectional Studies Databases Factual Diabetes Mellitus Type 2 Female Flavonoids Fruit Glycosides Humans Italy Male Middle Aged Nutritive Value Phenols Polyphenols Diet Diabetic Diet Healthy Patient ComplianceSettore MED/09 - Medicina InternaDatabases FactualCross-sectional studyMedicine (miscellaneous)Type 2 diabetesDiabeteAntioxidantsSettore MED/13 - EndocrinologiaFood groupCohort Studies0302 clinical medicineDiet DiabeticMedicineFood scienceGlycosidesAge; BMI; Diabetes; Diet; Flavonoids; Food groups; Geographical area; Intake; Phenolic acids; Polyphenols; TOSCA.IT study; Medicine (miscellaneous); Nutrition and DieteticsNutrition and DieteticsPhenolic acidDiabetesfood and beveragesMiddle AgedPolyphenols Flavonoids Phenolic acids Diabetes Food groups Diet Age BMI Geographical area Intake TOSCA.IT studyItalyToscaAgeBMIDiabetesDietFlavonoidsFood groupsGeographical areaIntakePhenolic acidsPolyphenolsTOSCA.IT studyCohortIntakeFemaleDiet HealthyNutritive ValueCohort studyPolyphenolPhenolic acids030209 endocrinology & metabolismBeverages03 medical and health sciencesBMIAgePhenolsDiabetes mellitusHumansAgedFlavonoidsGeographical area030109 nutrition & dieteticsbusiness.industryTOSCA.IT studyPolyphenolsAnthropometrymedicine.diseaseFood groupDietToscaCross-Sectional StudiesDiabetes Mellitus Type 2Food groupsPolyphenolCinnamatesAge; BMI; Diabetes; Diet; Flavonoids; Food groups; Geographical area; Intake; Phenolic acids; Polyphenols; TOSCA.IT studyFruitFlavonoidPatient Compliancebusiness
researchProduct

Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: A large Dutch population cohort

2017

BACKGROUND & AIMS Non-alcoholic fatty liver disease is an increasing health issue that develops rather unnoticed with obesity, type 2 diabetes mellitus and metabolic syndrome. We investigated prevalence, determinants and associated metabolic abnormalities of non-alcoholic fatty liver disease in the largest population-based cohort to date. METHODS Biochemical characteristics, type 2 diabetes mellitus and metabolic syndrome were determined in the Lifelines Cohort Study (N = 167,729), a population-based cohort in the North of the Netherlands. Non-alcoholic fatty liver disease was defined as Fatty Liver Index (FLI)≥60. Exclusion criteria were age <18 years, immigrants, missing data to assess FL…

0301 basic medicineMaleCirrhosislcsh:MedicineGastroenterologyBiochemistryGLOMERULAR-FILTRATION-RATESTEATOHEPATITISWhite Blood Cells0302 clinical medicineEndocrinologyNon-alcoholic Fatty Liver DiseaseRisk FactorsAnimal CellsPrevalenceMedicine and Health SciencesDiabetes diagnosis and managementlcsh:ScienceNetherlandsMETABOLIC SYNDROME2. Zero hungerINSULIN-RESISTANCEMultidisciplinaryLiver DiseasesFatty liverMiddle AgedLipids3. Good healthType 2 DiabetesCholesterolHypertension030211 gastroenterology & hepatologyFemaleAnatomyCellular TypesResearch ArticleAdultmedicine.medical_specialtyHbA1cEndocrine DisordersImmune CellsImmunologyUNITED-STATESGastroenterology and Hepatology03 medical and health sciencesInsulin resistanceInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumansHemoglobinHEPATIC STEATOSISHepatitisBlood Cellsbusiness.industryCholesterol HDLlcsh:RType 2 Diabetes MellitusBiology and Life SciencesProteinsRenal SystemCell Biologymedicine.diseaseDiagnostic medicineFatty LiverSERUM CREATININE VALUESRENAL-DISEASE030104 developmental biologyEndocrinologyCross-Sectional StudiesDiabetes Mellitus Type 2ATHEROSCLEROSISHyperglycemiaMetabolic DisordersRISK-FACTORSlcsh:QSteatohepatitisMetabolic syndromebusiness
researchProduct